机构：[1]Institute of Materia Medica, School of Pharmacy, North Sichuan Medical College, Nanchong, China.[2]School of Basic Medical Sciences &[3]Forensic Medicine, North Sichuan Medical College, Nanchong, China.[3]Medical imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, China.[4]Department of Anesthesiology, School of Clinical Medicine, North Sichuan Medical College, Nanchong, China.[5]Institute of Tissue Engineering and Stem Cells, Cancer Biotherapy Key Laboratory of Nanchong Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China.
Esophageal adenocarcinoma (EAC) is a highly lethal cancer associated with a rapidly rising incidence and a poor prognosis. Alantolactone, a sesquiterpene lactone isolated from inula helenium, has anti-inflammatory, antimicrobial, neuroprotective activities, and anticancer properties.In the present study, the anticancer effects of alantolactone on the human EAC cells were investigated in vitro and in vivo.After treated with alantolactone, the cell viability of KYAE-1, KYAE-2, OE19, OE33 cells reduced significantly compared with that of the control cells. Alantolactone induced apoptosis of the EAC cell lines by inhibiting the protein expression levels of nuclear factor erythroid2-related factor 2 (Nrf2). Furthermore, the apoptosis-inducing effect of alantolactone was enhanced by Nrf2 knockdown, while reduced by over-expression of Nrf2. Anti-oxidant α-tocopherol and glutathione can protect EAC cell lines against alantolactone A xenograft nude mice model showed that alantolactone can inhibit EAC growth in vivo.Alantolactone inhibits esophageal adenocarcinoma cells through Nrf2-mediated Reactive oxygen species (ROS) increment. Alantolactone maybe a potential therapeutical candidate for treating EAC.This article is protected by copyright. All rights reserved.
基金：
Project of the Bureau of Science &
Technology Nanchong City, Grant/Award
Numbers: 22SXQT0349, 19SXHZ0302,
19SXHZ0303, 18SXHZ0273, 18SXHZ0500;
Project for the First-class Pharmaceutical
Sciences of North Sichuan Medical
College; Training Program for College
Students’ Innovation and
Entrepreneurship, Grant/Award Numbers: 202210634031, S20211063003,
S20211063126, 202010634069,
202010634052; Opening Project of Medical
imaging Key Laboratory of Sichuan
Province, Grant/Award Number:
MIKLSP202005
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|3 区医学
小类|3 区毒理学3 区药学
最新[2023]版：
大类|4 区医学
小类|4 区药学4 区毒理学
第一作者：
第一作者机构：[1]Institute of Materia Medica, School of Pharmacy, North Sichuan Medical College, Nanchong, China.
共同第一作者：
通讯作者：
通讯机构：[1]Institute of Materia Medica, School of Pharmacy, North Sichuan Medical College, Nanchong, China.[*1]Institute of Materia Medica, School of Pharmacy, North Sichuan Medical College, Nanchong 637100, China.
